MyThera is a privately held company tracked for investment-relevant business and technology developments.
This slot renders the company's funding history: dates, rounds, amounts, valuations and lead investors once populated in data/funding-rounds.json.
MyThera's monthly GLP-1 candidate differentiated from weekly competitors (Lilly, Novo) and Phase 2 data confirmed monthly dosing feasibility, validating Pfizer's acquisition thesis to fill its obesity portfolio gap after internal programs failed on liver toxicity.